OmniAb, Inc.

OmniAb, Inc. (SEC CIK 0001846253), formerly known as Avista Public Acquisition Corp. II and traded on Nasdaq under the ticker APGB, is a life sciences-focused blank-check company sponsored by Avista Capital Partners. The SPAC completed its IPO in 2021, targeting opportunities in the healthcare and biotechnology sector. The entity filed a Form 10-Q/A, an amended quarterly report, with the SEC on January 12, 2022. The SPAC subsequently closed its business combination with Ligand Pharmaceuticals' antibody discovery platform in October 2022, with the combined company trading on Nasdaq under the ticker OABI. Sign up on SpacDesk for complete filing history, deal analytics, and real-time monitoring on this and every active SPAC.